ReviewClinical and vaccine immunology : CVI2010
How innate immune mechanisms contribute to antibody-enhanced viral infections.
Review in Clinical and vaccine immunology : CVI, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 140 citations in OpenAlex.
- Dengue virus envelope epitope-specific antibodies are associated with protection from severe dengue.EMBO molecular medicine · 2026Article
- Dengue and severe dengue.Clinical microbiology reviews · 2025Review
- Comparison of clinical and virological features in pediatric and adult dengue cases at Insein General Hospital during Myanmar's 2022 dengue season.Tropical medicine and health · 2025Article
- Genotype-Dependent Modulation of Macrophage Apoptosis and T Lymphocyte Responses by Duck Tembusu Virus Potentially Contributes to Genotype-Specific Immunopathogenesis.Transboundary and emerging diseases · 2025Article
- FcγRIIIA -activating antibodies in dengue virus infection reveals a distinct transient cross-reactive profile.Frontiers in immunology · 2025Article
- Current development of severe acute respiratory syndrome coronavirus 2 neutralizing antibodies (Review).Molecular medicine reports · 2024Review
- Production and Immunogenicity Assessment of LTp50: AnPharmaceuticals (Basel, Switzerland) · 2024Article
- Influence of previous Zika virus infection on acute dengue episode.PLoS neglected tropical diseases · 2023Article
- Antibody-dependent enhancement of porcine reproductive and respiratory syndrome virus infection downregulates the levels of interferon-gamma/lambdas in porcine alveolar macrophagesFrontiers in veterinary science · 2023Article
- Article
- Immune-Mediated Pathogenesis in Dengue Virus Infection.Viruses · 2022Review
- Antibody Dependent Enhancement of SARS-CoV-2 Infection in the Era of Rapid Vaccine Development.Medical archives (Sarajevo, Bosnia and Herzegovina) · 2022Review
- Review
- Article
- Review
- Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2022Review
- Vaccine-associated enhanced disease in humans and animal models: Lessons and challenges for vaccine development.Frontiers in microbiology · 2022Review
- Vaccine-Associated Enhanced Viral Disease: Implications for Viral Vaccine Development.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2021Review
- In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies.Cell · 2021Article
- Computational investigations of the immune response to repeated influenza infections and vaccinations.Royal Society open science · 2021Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preexisting antibodies may enhance viral infections. In dengue, nonneutralizing antibodies raised by natural infection with one of four dengue viruses (DENVs) may enhance infection with a different virus by a process we term "intrinsic antibody-dependent enhancement" (iADE). In addition, nonprotective antibodies raised by formalin-inactivated respiratory syncytial virus (RSV) and measles virus vaccines have led to enhanced disease during breakthrough infections. Infections under iADE conditions not only facilitate the process of viral entry into monocytes and macrophages but also modify innate and adaptive intracellular antiviral mechanisms, suppressing type 1 interferon (IFN) production and resulting in enhanced DENV replication. The suppression observed in vitro has been documented in patients with severe (dengue hemorrhagic fever [DHF]) but not in patient with mild (dengue fever [DF]) secondary dengue virus infections. Important veterinary viral infections also may exhibit iADE. It is thought that use of formalin deconforms viral epitopes of RSV, resulting in poor Toll-like receptor (TLR) stimulation; suboptimal maturation of dendritic cells with reduced production of activation factors CD40, CD80, and CD86; decreased germinal center formation in lymph nodes; and the production of nonprotective antibodies. These antibodies fail to neutralize RSV, allowing replication with secondary stimulation of RSV-primed Th2 cells producing more low-avidity antibody, resulting in immune complexes deposited into affected tissue. However, when formalin-inactivated RSV was administered with a TLR agonist to mice, they were protected against wild-type virus challenge. Safe and effective vaccines against RSV/measles virus and dengue virus may benefit from a better understanding of how innate immune responses can promote production of protective antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.